Dulaglutide: Mechanism, Research & UK Safety Profile
Also known as: Trulicity, LY2189265
Once-weekly GLP-1 receptor agonist licensed in the UK (Trulicity) for type 2 diabetes. UK prescription-only medicine.
Overview
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly. It is a long-acting fusion protein combining a modified GLP-1 analogue with a human IgG4 Fc fragment, conferring an extended half-life. Dulaglutide is MHRA-licensed for type 2 diabetes glycaemic control. The REWIND cardiovascular outcomes trial demonstrated MACE reduction in a high-CV-risk T2D population. Dulaglutide is also the active comparator in the SURPASS-CVOT trial of tirzepatide.
Discovery & Research History
Dulaglutide was developed through Eli Lilly's GLP-1 RA programme and approved by the FDA (2014) and EMA / MHRA (2014-2015) for type 2 diabetes. The AWARD phase 3 programme established efficacy and tolerability across multiple T2D populations. REWIND (2019) added a cardiovascular outcome signal in adults with T2D and high CV risk, including a sizeable primary-prevention subset.
Mechanism of Action
Dulaglutide is a GLP-1 receptor agonist with an Fc fusion extending half-life to approximately five days, supporting once-weekly dosing. It augments glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite via central GLP-1 receptor pathways.
Researched Effects
- HbA1c reduction in adults with type 2 diabetes (AWARD programme).
- Body-weight reduction (modest relative to anti-obesity-dose semaglutide or tirzepatide).
- Cardiovascular benefit in T2D with high CV risk (REWIND).
- Renal benefit signals in REWIND substudies.
Theoretical Research Protocols
- Dosage range
- Trial-arm doses are research records — see the primary publications for exact arms.
- Frequency
- Once weekly in licensed use.
- Duration
- Continuous in licensed use.
- Administration routes
- Subcutaneous (prefilled pen)
Safety Profile
Common side effects (research)
- Gastrointestinal events (nausea, diarrhoea, vomiting).
- Injection-site reactions.
Rare risks
- Acute pancreatitis (rare; class-monitored).
- Gallbladder events.
- Diabetic retinopathy worsening with rapid HbA1c reduction in susceptible patients.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 (per product information).
- Hypersensitivity to dulaglutide or excipients.
- Pregnancy and breastfeeding are typical contraindications.
UK Regulatory Status
United Kingdom (MHRA): MHRA-licensed prescription-only medicine (Trulicity) for type 2 diabetes.
European Union (EMA): EMA-licensed.
Notes: Dulaglutide should only be accessed via a qualified UK prescriber following appropriate clinical assessment. Active comparator in SURPASS-CVOT.
Related research resources
Key Research Studies
Gerstein HC et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet 2019.
REWIND demonstrated MACE reduction with dulaglutide in adults with T2D and high CV risk, including a substantial primary-prevention subset.
Read sourceNauck MA et al. AWARD programme summary — dulaglutide in type 2 diabetes
Pivotal phase 3 programme establishing the efficacy and tolerability of dulaglutide for T2D glycaemic control.
Frequently Asked Questions
What is dulaglutide?
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist licensed in the UK for type 2 diabetes. It is the active comparator in SURPASS-CVOT.
How does dulaglutide compare to semaglutide and tirzepatide?
Dulaglutide is a GLP-1 mono-agonist. Tirzepatide is a dual GLP-1/GIP agonist; semaglutide is a GLP-1 mono-agonist available at a higher anti-obesity dose. Cross-trial comparison should be done with care; SURPASS-CVOT is the head-to-head trial of tirzepatide versus dulaglutide.
Is dulaglutide licensed for obesity in the UK?
No. Dulaglutide is licensed for type 2 diabetes glycaemic control. Anti-obesity indications in the GLP-1 class are held by other agents (Wegovy, Saxenda, Mounjaro at the higher-dose obesity arm).